End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.92 CNY | +2.58% |
|
-4.85% | -9.55% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.55% | 2.19B | D+ | ||
+54.98% | 815B | C+ | ||
+44.25% | 654B | B | ||
-6.13% | 354B | C+ | ||
+21.36% | 337B | B- | ||
+11.09% | 302B | C+ | ||
+18.45% | 247B | B+ | ||
+2.09% | 229B | A+ | ||
+13.03% | 219B | B- | ||
+9.00% | 171B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000739 Stock
- Ratings Apeloa Pharmaceutical Co.,Ltd